Compumedics China JV Update


Compumedics Limited (ASX: CMP) shares an update regarding the contract negotiations with the Somfit technology which is China’s leading health-check organization, Meinian Onehealth Healthcare Holdings Co., Ltd. There was an announcement made in the month of May 2018 where the company has shared its contract negotiations with these two companies. However, now the company advises its customer about the delay in the contract negotiation due to some key issues which remains unresolved. These include that the interest of the Compumedics shareholder interests around the scope of intellectual property (“IP”) rights is not hampered and also their control and protection. These issues also consider the commercial conflicts of interest with a third party which in introduced in the joint venture discussions and were introduced at late stage in the in the process of negotiation and completion process. [optin-monster-shortcode id=”swikrbu1d9j9aq0o4cko”]

These issues, including commercial conflicts of interest with a third party introduced to the JV discussions, arose and/or were introduced at a late stage in the negotiation and completion process and no resolutions is expected to approach. In Spite of the complexities of the proposed investment transaction senior Health 100 executives have confirmed that still want to proceed with a Somfit trade.  Compumedics is no longer able to conclude a date in order to finalize JV with Health 100. As a result, Compumedics will be now be focusing on other trade and investment opportunities for the Somfit technology in China as well as other key international markets.

As per the FY18 performance review, the company generated revenue worth $37 million as a result of sales growth in international market for the core business. The company reported an EBITDA of $4.2 million as a result of profit generated through sales and also the operational improvement and efficiency gain. There was a strong growth in the NPAT despite of $0.7 million charged as tax. The core business grew by 8% only which was slower than what it was expected. The net cash position of the company is maintained. The net asset of the company is $23.2 million.

The current market price of the company is A$0.370 (AEST 4pm) with market capitalization of A$60.24 million and PE ratio 21.25x. As per the chart, the moving average convergence and divergence line is moving below the signal line but very near to each other.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report